PharmaSonics buoyed by anti-restenosis Sonotherapy data
This article was originally published in Clinica
Executive Summary
New data from a major trial of PharmaSonics' therapeutic ultrasound device for reducing restenosis could boost the momentum towards launching the product. This was the conclusion of the firm's CEO and president, Menahem Nassi, despite the fact that the results failed to meet the study's primary endpoint.